Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

multi-site phase 2 trial of XL784 was designed to enroll approximately 130 diabetic patients who have clinically significant proteinuria. Participants were randomly assigned to receive 200mg of XL784 or placebo daily for three months. The primary endpoint of the trial was a significant reduction in proteinuria compared with placebo. Secondary endpoints included changes in renal function and cardiovascular events.

About XL784

XL784 was the first small molecule compound developed by Exelixis, using its proprietary drug discovery engine. The compound is a potent inhibitor of the ADAM-10 and MMP-2 metalloprotease enzymes, targets of significant interest because of their important role in renal fibrosis and impairment. XL784 was specifically optimized to be matrix metalloprotease-1 (MMP-1) sparing, thus potentially significantly enhancing its safety profile and enabling higher dosing compared with other previously studied metalloprotease inhibitors. Results of single and repeat dose phase 1 clinical trials of XL784 administered orally to 70 healthy volunteers demonstrated that XL784 has attractive safety and pharmacokinetic profiles.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GSK, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... Research and Markets( http://www.researchandmarkets.com/research/c8jldk/global_healthcare ) has announced the ... report to their offering. The Global ... and CRM BPO to grow at a CAGR of ... a segment of outsourcing, which consists of subcontracting the ... that has the expertise in the required domains. It ...
(Date:5/27/2015)... LOUIS , May 27, 2015   Mallinckrodt Pharmaceuticals ... will present on Wednesday, June 10, 2015, at the Goldman ... Resort in Rancho Palos Verdes, Calif. ... Mark Trudeau , President and Chief Executive Officer, and ... Investor Relations Officer, will represent the company in a session ...
(Date:5/27/2015)... ATLANTA , May 27, 2015  MT ... which operates lawsuitsettlementnews.com, reports today the most up-to-date ... including Stryker , DePuy, Wright, ... however, certain litigations are still dragging on and ... Stryker Corporation: Stryker Corporation has agreed to pay ...
Breaking Medicine Technology:Global Healthcare BPO Market 2015-2019 - Emergence of Cloud-based BPO in Healthcare with Accenture, Cognizant, Genpact, IBM, TCS, Wipro & Xerox Dominating 2Mallinckrodt To Present At Goldman Sachs 36th Annual Healthcare Conference 2Major Hip Settlements Reported by Lawsuitsettlementnews.com 2Major Hip Settlements Reported by Lawsuitsettlementnews.com 3
... HERZELIYA, Israel, September 30 Medical device ... round led by 7 Health,Ventures. Previous investors: Ofer ... as well. , ActiViews, ... used,in Computer Tomography (CT), fluoroscopy and Magnetic Resonance ...
... , JERUSALEM, Israel, September 30 ... evaluating carlecortemcel-l, the generic,name of what is widely known ... leukemia and lymphoma. The article, carlecortemcel-l, an ex vivo ... by,Dr. Ka Wah Chan and Dr. Demetrios Petropoulos, will ...
Cached Medicine Technology:Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 2Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma 3
(Date:5/27/2015)... Representatives from Classified Advertising Plus, LLC, ... the American Immigration Lawyers Association (AILA). The conference takes ... booth is #404. , The annual event is billed ... a regular AILA conference attendee, describes it as “kind ... clients to their booth and make fresh friends among ...
(Date:5/27/2015)... 27, 2015 National Healthcare ... award winning web development and interactive marketing ... the launch of its newly redesigned, custom ... National Healthcare Providers, is a physician owned ... the areas of Radiology, Anesthesiology, Emergency and ...
(Date:5/27/2015)... Water, Inc. , an industry ... announced that its elite BG-12000 Body Glove Water ... pass the new NSF/ANSI Standard 401 – Pharmaceuticals: ... that the BG-12000 by Water, Inc. significantly reduces ... chemicals used in manufacturing that are currently found ...
(Date:5/27/2015)... Net Pistol proudly welcomes two new ... , The Mobility Van Store of Lakeland, Florida, is ... the mobility industry. They have a team of trained ... pre-owned wheelchair-accessible van, truck or car. Additionally, they provide ... chairs, three and four-wheel scooters, and manual wheelchairs. , ...
(Date:5/27/2015)... Chicago, IL (PRWEB) May 27, 2015 The ... Chicago office is open for business to better serve ... is in the Jefferson Park neighborhood on the Northwest side ... Chicago. Appointments can be arranged by calling the Chicago ... location for the Advanced Fertility Center of Chicago. The ...
Breaking Medicine News(10 mins):Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 2Health News:PERM Specialists from MCAads.com Will Attend the 2015 Conference on Immigration Law Set for June 17-20 in the DC Metro Area 3Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 2Health News:National Healthcare Providers Showcases Expanded Business Model with Launch of New Website 3Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 2Health News:Water, Inc.’s BG-12000 Body Glove Water Filter System Receives NSF/ANSI Standard 401 Certification for Pharmaceutical Emerging Contaminant Reduction 3Health News:Net Pistol Continues Success Serving Mobility Dealers 2Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2
... in combination with ribavirin for previously untreated children with ... , KENILWORTH, N.J., Dec. 12 ... announced that the U.S. Food and Drug Administration (FDA) ... REBETOL(R) (ribavirin, USP) combination therapy for use in previously ...
... Mich., Dec. 12 Terumo Corporation and Terumo,s,subsidiary, ... entered into an agreement to settle all outstanding ... a number of lawsuits pending,in which each claims ... litigations all,involve methods and devices used in endoscopic ...
... Dignity of a Person), an Instruction from the Vatican Congregation ... arising from biomedical research, provides guidance on how to respect ... said Cardinal Francis George of Chicago, president of the United ... "We welcome the Instruction as theologians, medical personnel, ...
... could also perpetuate more allergies among kids, , , FRIDAY, ... allergies are on the rise, with more and more ... are responding by providing nut-free areas. , But, at ... far, even creating hysteria over potential nut exposures. What,s ...
... up is hard,to do-but with the sixth annual ... all of the tools to help Americans ditch ... 2009. America,s largest and most,comprehensive multiplatform fitness ... provides participants unprecedented resources and,support -- online, on ...
... the launch of ATSU,s Women,s Wellness Program , ... ... noted scientist, author, and stroke survivor, joined A.T. Still University (ATSU) ... Program Nov. 18 at the Hilton Scottsdale Resort and Villas. Dr. ...
Cached Medicine News:Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 2Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 3Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 4Health News:Nut Bans in Schools May Be Spurring Hysteria 2Health News:Nut Bans in Schools May Be Spurring Hysteria 3Health News:Discovery Health's NATIONAL BODY CHALLENGE Weighs in for a Sixth Season, Urging Americans to Break up With Bad Habits 2Health News:Discovery Health's NATIONAL BODY CHALLENGE Weighs in for a Sixth Season, Urging Americans to Break up With Bad Habits 3Health News:Discovery Health's NATIONAL BODY CHALLENGE Weighs in for a Sixth Season, Urging Americans to Break up With Bad Habits 4Health News:Jill Bolte Taylor Keynotes ATSU Women's Wellness Luncheon 2Health News:Jill Bolte Taylor Keynotes ATSU Women's Wellness Luncheon 3
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 13.0 mm and length 15 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 9.0 mm and length 9 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 7 mm....
Medicine Products: